Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus for TSC-associated Refractory Seizures
NCT01713946Phase 3Completed
- Sponsor
- Novartis
- Start
- Apr 2013
- Primary completion
- Oct 2017
- Modality
- Small Molecules
- Countries
- 25
01
Overview
A Phase 3 trial of everolimus in tuberous sclerosis complex (TSC), sponsored by Novartis. Started Apr 2013; status: completed.
02
Drugs
everolimus
03
Conditions
tuberous sclerosis complex (TSC)
Beyond the preview
Go deeper on NCT01713946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01713946.